Omentin-1 vs PACAP-38
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | PACAP-38 |
|---|---|---|
| Category | Diabetes & Metabolic | Cognitive Enhancement |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | ~35 kDa | 4534 Da |
| Half-Life | hours | minutes |
| Amino Acids | 313 | 38 aa |
| Typical Dose | No approved human dose; research use only | 10-100 µg preclinical range |
| Route | IV|SC | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 650 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
Omentin-1 Dosing
not established|not established
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.